Matthew W. Foehr, CEO of Ligand Pharmaceuticals, holds a Bachelor of Science degree in Biology from Santa Clara University and has a strong background in biotechnology. He became the CEO after serving as the President and Chief Operating Officer for...
Matthew W. Foehr, CEO of Ligand Pharmaceuticals, holds a Bachelor of Science degree in Biology from Santa Clara University and has a strong background in biotechnology. He became the CEO after serving as the President and Chief Operating Officer for the company. Foehr has more than 17 years of experience in managing global research and development programs, notably leading the R&D integration of Stiefel into GlaxoSmithKline after its $3.6 billion acquisition in 2009. He has authored multiple scientific publications and is associated with several U.S. patents. For 2021, he received total compensation of approximately $779,667, comprising a salary of $520,200 and an annual bonus of $259,467. Notably, he has played a significant role in advancing Ligand's operations, focusing on performance metrics such as revenue growth and licensing agreements. His leadership has been marked by strategic decision-making that emphasizes the company's long-term goals while adapting to changes in the pharmaceutical landscape.